BamSEC and AlphaSense Join Forces
Learn More

Iovance Biotherapeutics Inc.

NASDAQ: IOVA    
Share price (8/22/25): $2.69    
Market cap (8/22/25): $973 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 26 pages Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan as Amended
12/34/56
EX-10.1
from 10-Q 17 pages Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan as Amended ​
12/34/56
EX-10.55
from 10-K 5 pages Agreement for Termination of Lease and Voluntary Surrender of Premises
12/34/56
EX-10.54
from 10-K 12 pages 2.premises: Sublessor Hereby Subleases to Sublessee, and Sublessee Hereby Subleases From Sublessor, a Portion of the Premises Consisting of Approximately 16,731 Rentable Square Feet of Space Located on the First Floor of the Building (Hereinafter, the “Subleased Premises”). the Subleased Premises Are More Particularly Described on Exhibit B Attached Hereto. Except to the Extent That the Square Footage of the Premises Is Reduced Under the Master Lease, the Square Footage of the Subleased Premises Shall Be as Set Forth in This Paragraph, Notwithstanding Any Remeasurement. Sublessor Has Delivered to Sublessee a Cad File of the FF&E in the Subleased Premises. 3. Term
12/34/56
EX-10.43
from 10-K 11 pages Executive Employment Agreement
12/34/56
EX-10.42
from 10-K 11 pages Executive Employment Agreement
12/34/56
EX-10.31
from 10-K 5 pages Portions of This Exhibit Have Been Redacted Because They Are Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”
12/34/56
EX-10.30
from 10-K 7 pages Portions of This Exhibit Have Been Redacted Because They Are Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”
12/34/56
EX-10.2
from 10-Q 28 pages Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan as Amended
12/34/56
EX-10.1
from 10-Q 17 pages Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan as Amended
12/34/56
EX-10.2
from 10-Q 27 pages Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan as Amended
12/34/56
EX-10.1
from 10-Q 18 pages Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Equity Incentive Plan
12/34/56
EX-10.2
from 10-Q 17 pages Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan as Amended
12/34/56
EX-10.1
from 10-Q 27 pages Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan as Amended
12/34/56
EX-10.1
from 8-K/A 108 pages Dated January 2023 Option Agreement Relating to the Operations of the Proleukin Business Between Clinigen Holdings Limited as Share Seller Clinigen Healthcare Limited as Chcl Clinigen, Inc. as Clinigen US Iovance Biotherapeutics Uk Ltd as Purchaser Iovance Biotherapeutics, Inc. as Purchaser’s Guarantor White & Case Llp 5 Old Broad Street London Ec2n 1dw
12/34/56
EX-10.2
from 10-Q 7 pages Iovance Biotherapeutics, Inc. Deferred Restricted Stock Unit Notice Under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as Amended
12/34/56
EX-10.1
from 10-Q 18 pages Iovance Biotherapeutics, Inc. ​ 2018 Equity Incentive Plan as Amended ​
12/34/56
EX-10.46
from 10-K 10 pages Third Amendment to Lease Agreement
12/34/56
EX-10.13
from 10-K 16 pages Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Equity Incentive Plan
12/34/56
EX-10.3
from 8-K 9 pages Iovance Biotherapeutics, Inc. Stock Unit Notice Under the Iovance Biotherapeutics, Inc. 2021 Inducement Equity Incentive Plan, as Amended
12/34/56